A PYMNTS Company

US: New inversion rules threaten Allergan-Pfizer merger

By  |  April 5, 2016

America’s Treasury Department has unveiled new rules making it harder for companies to pull off tax-avoiding corporate “inversion” deals, raising questions over the forthcoming $160bn merger of US-based Pfizer and Dublin-domiciled Allergan.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The changes follow sharp criticism of Pfizer’s and Allergan’s pending merger, which will see Pfizer relocate its headquarters from the US to Dublin, where corporation tax is much lower.

    The merger, which will be the largest healthcare deal in history when it completes, was slammed by US lawmakers when it was announced last November as the latest in a series of transactions in which US-based companies move their legal addresses overseas to take advantage of lower tax rates. Allergan operates out of New Jersey and does most of its business in the US, but has its headquarters in Dublin.

    The pharmaceutical companies said they were reviewing the Treasury Department’s notice. “Prior to completing the review, we won’t speculate on any potential impact,” they said.

    Full content: NPR

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.